Incyte Corp
INCYHealthcare|Biotechnology|USA
$93.59
-1.27 (-1.34%)
DCF (FCF)
$55.64
Tangible Book
$24.78
Graham Number
$61.53
Earnings Power
$50.38
About
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
Stock Price
+51.9%(1Y)
Pipeline Summary
478 total trials184
Phase 1
259
Phase 2
75
Phase 3
3
Phase 4
Active: 45NO_LONGER_AVAILABLE: 6Completed: 195Recruiting: 105Terminated: 88Withdrawn: 21NOT_YET_RECRUITING: 10AVAILABLE: 3APPROVED_FOR_MARKETING: 2Unknown: 3
Active Trials (150)
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
NCT04455841Anemia
Phase 1Phase 2Active
Enrollment: 84 participants
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
NCT04577014Soft Tissue Sarcoma
Phase 1Phase 2Recruiting
Enrollment: 98 participants
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
NCT04659616Acute Myeloid Leukemia
Phase 1Recruiting
Enrollment: 32 participants
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)
NCT04661007Non Hodgkins Lymphoma
Phase 1Phase 2Active
Enrollment: 72 participants
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
NCT07104565Immune Thrombocytopenia
Phase 2Recruiting
Enrollment: 56 participants
BioScore
6.4/10
Watchlist
Ownership
Recent Insider Trades
CAGNONI PABLO JSELL
2026-03-1718,667 shares @ $94.24
CAGNONI PABLO JSELL
2026-02-1918,668 shares @ $100.91
Issa Mohamed KhairieSELL
2026-01-0710,856 shares @ $109.07
Stein Steven HSELL
2026-01-0515,634 shares @ $101.7
Tray ThomasSELL
2025-12-193,374 shares @ $99.69
Recent News
2026-03-30 23:30:09
2026-03-30 20:31:41
2026-03-28 20:00:02
2026-03-26 14:30:09
2026-03-25 16:31:56
Data last updated: Apr 7, 2026, 02:27 PM